Eloxx Pharmaceuticals Inc
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of RNA-modulating drugs in the United States. The company develops ELX-02, which is in phase II clinical trial for the treatment of nonsense mutation alport syndrome; ZKN013, which is in investigation phase for the treatment of nonsense mutation recessive dystrophic and junctional epidermolysis bul… Read more
Eloxx Pharmaceuticals Inc (ELOX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2023: 0.172x
Based on the latest financial reports, Eloxx Pharmaceuticals Inc (ELOX) has a cash flow conversion efficiency ratio of 0.172x as of September 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.45 Million) by net assets ($-20.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Eloxx Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1998–2022)
This chart illustrates how Eloxx Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Eloxx Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eloxx Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CHINA WINDPOWER - Dusseldorf Stock Exchang
DU:HK51
|
N/A |
|
BACKBONE Technology AG
MU:AO9
|
N/A |
|
DIAMOND FIELDS RES
F:D2DA
|
N/A |
|
Agstar PLC
CM:AGSTN0000
|
N/A |
|
IMPACT MIN
BE:IUB
|
N/A |
|
Shaheen Insurance Company Ltd
KAR:SHNI
|
N/A |
|
FOACW
PINK:FOACW
|
N/A |
|
El Wadi For International and Investement Development
EGX:WACE
|
N/A |
Annual Cash Flow Conversion Efficiency for Eloxx Pharmaceuticals Inc (1998–2022)
The table below shows the annual cash flow conversion efficiency of Eloxx Pharmaceuticals Inc from 1998 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $-10.66 Million | $-31.84 Million | 2.987x | +291.05% |
| 2021-12-31 | $22.38 Million | $-35.00 Million | -1.564x | +45.71% |
| 2020-12-31 | $9.78 Million | $-28.17 Million | -2.880x | -164.79% |
| 2019-12-31 | $36.21 Million | $-39.39 Million | -1.088x | -48.81% |
| 2018-12-31 | $42.91 Million | $-31.37 Million | -0.731x | +96.00% |
| 2017-12-31 | $871.21K | $-15.94 Million | -18.291x | -2169.12% |
| 2016-12-31 | $4.56 Million | $-3.68 Million | -0.806x | -34.17% |
| 2015-12-31 | $12.22 Million | $-7.34 Million | -0.601x | -239.27% |
| 2014-12-31 | $27.49 Million | $-4.87 Million | -0.177x | +82.82% |
| 2013-12-31 | $3.79 Million | $-3.90 Million | -1.031x | +18.85% |
| 2012-12-31 | $3.45 Million | $-4.39 Million | -1.270x | -6.43% |
| 2011-12-31 | $4.52 Million | $-5.39 Million | -1.193x | -100.82% |
| 2010-12-31 | $7.98 Million | $-4.74 Million | -0.594x | -17.23% |
| 2009-12-31 | $7.82 Million | $-3.96 Million | -0.507x | -107.29% |
| 2008-12-31 | $9.84 Million | $-2.41 Million | -0.245x | +67.62% |
| 2007-12-31 | $2.69 Million | $-2.03 Million | -0.755x | +11.88% |
| 2006-12-31 | $2.95 Million | $-2.53 Million | -0.857x | -126.45% |
| 2005-12-31 | $5.59 Million | $-2.12 Million | -0.379x | +5.42% |
| 2004-12-31 | $4.73 Million | $-1.89 Million | -0.400x | +42.91% |
| 2003-12-31 | $2.86 Million | $-2.00 Million | -0.701x | -155.58% |
| 2002-12-31 | $4.79 Million | $-1.31 Million | -0.274x | -103.82% |
| 2001-12-31 | $-206.71K | $-1.48 Million | 7.178x | +703.45% |
| 2000-12-31 | $1.52 Million | $-1.81 Million | -1.190x | -11.43% |
| 1999-12-31 | $912.17K | $-973.77K | -1.068x | -18.58% |
| 1998-12-31 | $1.08 Million | $-973.77K | -0.900x | -- |